REVA bags $42m from Medtronic et al:
This article was originally published in Clinica
Executive Summary
San Diego, California-based REVA Medical has secured $42m to fund the development of its bioresorbable stents for the treatment of arterial disease. The funds were raised in a private financing round led by Cerberus Capital Management and Brookside Capital, and contributed to by new shareholders Medtronic and Pequot Management, along with existing investors Domain Partners and Group Outcome. REVA will use the proceeds to take its stents to clinical trials.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.